R82.90 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2018/2019 edition of ICD-10-CM R82.90 became effective on October 1, 2018. This is the American ICD-10-CM version of R82.90 - other international versions of ICD-10 R82.90 may differ.
Retention of urine, unspecified. R33.9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2020 edition of ICD-10-CM R33.9 became effective on October 1, 2019.
Inability to empty the urinary bladder with voiding (urination). Incomplete emptying of the bladder; ICD-10-CM R33.9 is grouped within Diagnostic Related Group(s) (MS-DRG v 38.0): 695 Kidney and urinary tract signs and symptoms with mcc; 696 Kidney and urinary tract signs and symptoms without mcc; 791 Prematurity with major problems
R31.9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM R31.9 became effective on October 1, 2021. This is the American ICD-10-CM version of R31.9 - other international versions of ICD-10 R31.9 may differ.
N39. 0 - Urinary tract infection, site not specified | ICD-10-CM.
87086 Culture, bacterial; quantitative, colony count, urine.
Code Z13. 89, encounter for screening for other disorder, is the ICD-10 code for depression screening.
Unspecified symptoms and signs involving the genitourinary system. R39. 9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM R39.
Healthcare providers often use urinalysis to screen for or monitor certain common health conditions, such as liver disease, kidney disease and diabetes, and to diagnose urinary tract infections (UTIs).
If culture is positive, CPT code(s): 87088 (each isolate) will be added with an additional charge. Identification will be performed at an additional charge (CPT code(s): 87077 or 87140 or 87143 or 87147 or 87149).
ICD-10 code Z13. 40 for Encounter for screening for unspecified developmental delays is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
39 (Encounter for other screening for malignant neoplasm of breast). Z12. 39 is the correct code to use when employing any other breast cancer screening technique (besides mammogram) and is generally used with breast MRIs.
N39. 0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM N39. 0 became effective on October 1, 2021.
ICD-10 code R39. 9 for Unspecified symptoms and signs involving the genitourinary system is a medical classification as listed by WHO under the range - Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified .
9: Fever, unspecified.
ICD-10-CM Code for Acute cystitis with hematuria N30. 01.
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Urine specimen: The patient should not have urinated for at least one hour prior to specimen collection. Direct patient to provide a first-catch urine (approximately 20 mL to 30 mL of the initial urine stream) into a urine collection container free of any preservatives.
The patient should not have urinated for at least one hour prior to specimen collection.
Specimen with incorrect patient identification; unlabeled specimen; inappropriate specimen transport conditions; specimens received after prolonged delay (usually >72 hours); specimen leaked in transit; specimen in expired transport or incorrect transport device; specimens with inappropriate source for test requested; specimen with fixative or additives; Aptima® urine transport >30 days from collection; Aptima® urine transport with incorrect specimen volume; specimen in ProbeTec™ UPT transport; ProbeTec™ Q-swabs; urine in sterile container.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary.